Tag
NASDAQ: MIRM
- Vir Biotechnology meets Phase 3 hepatitis delta endpoint with 44% response
- Pharming Group reports 26.4% spleen reduction in Phase 2 leniolisib trial
- Mirum Pharmaceuticals reports LIVMARLI met Phase 3 EXPAND endpoint
- Egetis Therapeutics AB wins FDA approval for Emcitate in MCT8 deficiency
- Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older